Deep Track Capital, LP
Q2 2025 13F-HR Holdings
Net value change ($000)
+30,016
(1.0%)
New positions
7
Sold out positions
11
Turnover %
18.1%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q1 2025
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| INSM | 156,685 | 806.2% |
| AXSM | 83,655 | NEW |
| IONS | 55,563 | 40.4% |
| PCVX | 41,577 | 146.8% |
| GPCR | 35,506 | 50.0% |
| PTGX | 34,321 | 23.7% |
| AKRO | 32,401 | 24.9% |
| OCUL | 27,874 | 26.6% |
| 89bio, Inc. | 25,560 | 37.7% |
| JBIO | 25,068 | NEW |
Top Reduces (Value $000, Stocks/ETFs)
| Intra-Cellular Therapies, Inc. | -263,840 | -100.0% |
| BBIO | -57,934 | -59.9% |
| DVAX | -54,264 | -23.5% |
| SRPT | -52,978 | -92.3% |
| AMGN | -35,216 | -100.0% |
| EWTX | -30,800 | -100.0% |
| DYN | -20,920 | -100.0% |
| GLPG | -18,616 | -100.0% |
| Sage Therapeutics, Inc. | -16,209 | -100.0% |
| KRRO | -11,755 | -77.2% |
Instrument mix + QoQ Δ (ex-options)
Derivatives reported exposure ($000):
7,695
(0.2% of total reported value)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|